YIH
IOVA icon

Y-Intercept (HK)’s Iovance Biotherapeutics IOVA Stock Holding History

Y-Intercept (HK)’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,250
Closed -$241K – 1630
2024
Q1 		$241K Buy
+16,250
New +$189K 0.02% 1069
2022
Q2 		– Sell
-31,084
Closed -$518K – 1020
2022
Q1 		$518K Buy
+31,084
New +$481K 0.12% 247
2021
Q2 		– Sell
-18,813
Closed -$558K – 748
2021
Q1 		$558K Buy
18,813
+13,802
+275% +$572K 0.15% 227
2020
Q4 		$244K Buy
+5,011
New +$199K 0.1% 382

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Y-Intercept (HK)'s IOVA Position: Q2 2024 in Review

Y-Intercept (HK) sold out of Iovance Biotherapeutics (IOVA) in Q2 2024, closing a stake of 16,250 shares — an estimated $241K sold.

Y-Intercept (HK) first reported a position in IOVA in Q4 2020 and held it in 4 quarters. The position peaked at $558K in Q1 2021. 295 funds tracked by Wall St. Rank hold IOVA as of Q2 2024.

  • Y-Intercept (HK) reported no remaining Iovance Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 16,250 Iovance Biotherapeutics shares in Q2 2024, an estimated $241K.
  • Y-Intercept (HK) first reported a position in Iovance Biotherapeutics in Q4 2020 and held it in 4 quarters.
  • Y-Intercept (HK)'s Iovance Biotherapeutics position peaked at $558K in Q1 2021.
  • 295 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2024.

Based on Y-Intercept (HK)'s 13F filing for Q2 2024, filed 14 Aug 2024.